Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer

Bo Ram Kim, Yoon A. Jeong, Min Jee Jo, Seong Hye Park, Yoo Jin Na, Jung Lim Kim, Soyeon Jeong, Hye Kyeong Yun, Sanghee Kang, Dae Hee Lee, Sang Cheul Oh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite an increase in the survival rate of patients with cancer owing to the use of current chemotherapeutic agents, adverse effects of cancer therapies remain a concern. Combination therapies have been developed to increase efficacy, reduce adverse effects, and overcome drug resistance. Genipin is a natural product derived from Gardenia jasminoides, which has been associated with anti-inflammatory, anti-angiogenic, and anti-proliferative effects; hypertension; and anti-ischemic brain injuries. However, the enhancement of oxaliplatin sensitivity by genipin remains unexplored. Our study showed that a combination of genipin and oxaliplatin exerts synergistic antitumor effects in vitro and in vivo in colorectal cancer cell lines through the reactive oxygen species (ROS)/endoplasmic reticulum (ER) stress/BIM pathway. Importantly, the combination did not affect normal colon cells. BIM knockdown markedly inhibited apoptosis induced by the combination. In addition, genipin induced ROS by inhibiting superoxide dismutase 3 activity. These findings suggest that genipin may be a novel agent for increasing the sensitivity of oxaliplatin against colorectal cancer. The combination of oxaliplatin and genipin hold significant therapeutic potential with minimal adverse effects.

Original languageEnglish
Pages (from-to)751-761
Number of pages11
JournalMolecular cancer therapeutics
Volume18
Issue number4
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

oxaliplatin
Therapeutic Uses
Colorectal Neoplasms
Reactive Oxygen Species
Gardenia
Endoplasmic Reticulum Stress
Biological Products
Drug Resistance
Brain Injuries
Superoxide Dismutase
genipin
Neoplasms
Colon
Anti-Inflammatory Agents
Therapeutics
Survival Rate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer. / Kim, Bo Ram; Jeong, Yoon A.; Jo, Min Jee; Park, Seong Hye; Na, Yoo Jin; Kim, Jung Lim; Jeong, Soyeon; Yun, Hye Kyeong; Kang, Sanghee; Lee, Dae Hee; Oh, Sang Cheul.

In: Molecular cancer therapeutics, Vol. 18, No. 4, 01.04.2019, p. 751-761.

Research output: Contribution to journalArticle

Kim, BR, Jeong, YA, Jo, MJ, Park, SH, Na, YJ, Kim, JL, Jeong, S, Yun, HK, Kang, S, Lee, DH & Oh, SC 2019, 'Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer', Molecular cancer therapeutics, vol. 18, no. 4, pp. 751-761. https://doi.org/10.1158/1535-7163.MCT-18-0196
Kim, Bo Ram ; Jeong, Yoon A. ; Jo, Min Jee ; Park, Seong Hye ; Na, Yoo Jin ; Kim, Jung Lim ; Jeong, Soyeon ; Yun, Hye Kyeong ; Kang, Sanghee ; Lee, Dae Hee ; Oh, Sang Cheul. / Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer. In: Molecular cancer therapeutics. 2019 ; Vol. 18, No. 4. pp. 751-761.
@article{d5bc11446929456d92e2baecbe4f7d2c,
title = "Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer",
abstract = "Despite an increase in the survival rate of patients with cancer owing to the use of current chemotherapeutic agents, adverse effects of cancer therapies remain a concern. Combination therapies have been developed to increase efficacy, reduce adverse effects, and overcome drug resistance. Genipin is a natural product derived from Gardenia jasminoides, which has been associated with anti-inflammatory, anti-angiogenic, and anti-proliferative effects; hypertension; and anti-ischemic brain injuries. However, the enhancement of oxaliplatin sensitivity by genipin remains unexplored. Our study showed that a combination of genipin and oxaliplatin exerts synergistic antitumor effects in vitro and in vivo in colorectal cancer cell lines through the reactive oxygen species (ROS)/endoplasmic reticulum (ER) stress/BIM pathway. Importantly, the combination did not affect normal colon cells. BIM knockdown markedly inhibited apoptosis induced by the combination. In addition, genipin induced ROS by inhibiting superoxide dismutase 3 activity. These findings suggest that genipin may be a novel agent for increasing the sensitivity of oxaliplatin against colorectal cancer. The combination of oxaliplatin and genipin hold significant therapeutic potential with minimal adverse effects.",
author = "Kim, {Bo Ram} and Jeong, {Yoon A.} and Jo, {Min Jee} and Park, {Seong Hye} and Na, {Yoo Jin} and Kim, {Jung Lim} and Soyeon Jeong and Yun, {Hye Kyeong} and Sanghee Kang and Lee, {Dae Hee} and Oh, {Sang Cheul}",
year = "2019",
month = "4",
day = "1",
doi = "10.1158/1535-7163.MCT-18-0196",
language = "English",
volume = "18",
pages = "751--761",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer

AU - Kim, Bo Ram

AU - Jeong, Yoon A.

AU - Jo, Min Jee

AU - Park, Seong Hye

AU - Na, Yoo Jin

AU - Kim, Jung Lim

AU - Jeong, Soyeon

AU - Yun, Hye Kyeong

AU - Kang, Sanghee

AU - Lee, Dae Hee

AU - Oh, Sang Cheul

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Despite an increase in the survival rate of patients with cancer owing to the use of current chemotherapeutic agents, adverse effects of cancer therapies remain a concern. Combination therapies have been developed to increase efficacy, reduce adverse effects, and overcome drug resistance. Genipin is a natural product derived from Gardenia jasminoides, which has been associated with anti-inflammatory, anti-angiogenic, and anti-proliferative effects; hypertension; and anti-ischemic brain injuries. However, the enhancement of oxaliplatin sensitivity by genipin remains unexplored. Our study showed that a combination of genipin and oxaliplatin exerts synergistic antitumor effects in vitro and in vivo in colorectal cancer cell lines through the reactive oxygen species (ROS)/endoplasmic reticulum (ER) stress/BIM pathway. Importantly, the combination did not affect normal colon cells. BIM knockdown markedly inhibited apoptosis induced by the combination. In addition, genipin induced ROS by inhibiting superoxide dismutase 3 activity. These findings suggest that genipin may be a novel agent for increasing the sensitivity of oxaliplatin against colorectal cancer. The combination of oxaliplatin and genipin hold significant therapeutic potential with minimal adverse effects.

AB - Despite an increase in the survival rate of patients with cancer owing to the use of current chemotherapeutic agents, adverse effects of cancer therapies remain a concern. Combination therapies have been developed to increase efficacy, reduce adverse effects, and overcome drug resistance. Genipin is a natural product derived from Gardenia jasminoides, which has been associated with anti-inflammatory, anti-angiogenic, and anti-proliferative effects; hypertension; and anti-ischemic brain injuries. However, the enhancement of oxaliplatin sensitivity by genipin remains unexplored. Our study showed that a combination of genipin and oxaliplatin exerts synergistic antitumor effects in vitro and in vivo in colorectal cancer cell lines through the reactive oxygen species (ROS)/endoplasmic reticulum (ER) stress/BIM pathway. Importantly, the combination did not affect normal colon cells. BIM knockdown markedly inhibited apoptosis induced by the combination. In addition, genipin induced ROS by inhibiting superoxide dismutase 3 activity. These findings suggest that genipin may be a novel agent for increasing the sensitivity of oxaliplatin against colorectal cancer. The combination of oxaliplatin and genipin hold significant therapeutic potential with minimal adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=85064198805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064198805&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-18-0196

DO - 10.1158/1535-7163.MCT-18-0196

M3 - Article

C2 - 30787174

AN - SCOPUS:85064198805

VL - 18

SP - 751

EP - 761

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -